Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Recommendation of “Hold” by Brokerages

Pulmonx Corporation (NASDAQ:LUNG) has been assigned an average rating of “Hold” from the ten ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $7.6643.

LUNG has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research note on Wednesday, October 8th. D. Boral Capital reissued a “buy” rating and set a $16.00 price target on shares of Pulmonx in a research note on Monday, September 8th. Lake Street Capital lowered their target price on Pulmonx from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, July 31st. Wells Fargo & Company lowered their target price on shares of Pulmonx from $6.00 to $3.00 and set an “equal weight” rating for the company in a research note on Friday, August 1st. Finally, Piper Sandler downgraded shares of Pulmonx from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $9.00 to $2.50 in a research report on Thursday, July 31st.

Hedge Funds Weigh In On Pulmonx

Hedge funds and other institutional investors have recently modified their holdings of the stock. Corton Capital Inc. acquired a new position in Pulmonx in the 2nd quarter worth approximately $32,000. R Squared Ltd bought a new stake in Pulmonx in the 2nd quarter valued at $41,000. Bank of Montreal Can acquired a new stake in Pulmonx during the second quarter worth about $53,000. Vontobel Holding Ltd. bought a new stake in Pulmonx in the 1st quarter valued at $82,000. Finally, Los Angeles Capital Management LLC bought a new position in Pulmonx during the second quarter worth about $84,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Price Performance

Shares of NASDAQ:LUNG opened at $1.67 on Tuesday. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.35 and a quick ratio of 4.63. Pulmonx has a 12 month low of $1.47 and a 12 month high of $9.37. The firm has a market capitalization of $68.05 million, a P/E ratio of -1.17 and a beta of 0.42. The company’s fifty day moving average price is $1.66 and its 200 day moving average price is $2.80.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. The business had revenue of $23.86 million for the quarter, compared to analyst estimates of $23.46 million. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. Pulmonx has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Pulmonx will post -1.55 earnings per share for the current fiscal year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.